Adicet Bio Inc (ACET) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.18 (+1.89%), Market cap $0.08B, 52-week low–high $0.47 ~ $8.82.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for Adicet Bio Inc are updated in real time on BlackAll Trade.
Adicet Bio Inc trades at $9.18 (+1.89%). Real-time quotes and charts are available on BlackAll Trade.
Adicet Bio Inc has a market cap of about $0.08B.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead pro